OPRX · OptimizeRx Corp
5 customers — 47% of revenue (year ended December 31, 2025)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
One customer — 10% of revenue (fiscal 2025)
“one customer that accounted for approximately 10% of total revenue in fiscal 2025 did not generate revenue during the current period, and future revenue from this customer is uncertain.”
3 customers — 10% of revenue (fiscal 2025)
“In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
5 customers — 49% of revenue (year ended December 31, 2024)
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively.”
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-12 |
OptimizeRx Announces Finance Leadership Appointments to Support the Next Phase of Growth
The Company Names Andy D’Silva as the next Chief Financial Officer and Heather Favazza as Chief Accounting Officer effective January 1, 2027 Planned Transition Reflects Strong Succession Planning and Deep Leadership Bench WALTHAM, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. |
| 2026-08-12 |
OptimizeRx Reports Second Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q2 revenue totals $20.5 million – Q2 net loss and adjusted EBITDA of $(0.7) million and $4.9 million, respectively – Reaffirms fiscal year 2026 revenue guidance of $95 - $100 million and adjusted EBITDA guidance of $21 - $25 million – Completed debt refinancing with $35 million traditional |
| 2026-07-29 |
OptimizeRx Sets Second Quarter 2026 Conference Call for August 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at the most important decision points, will hold a |
| 2026-07-23 |
OptimizeRx Appoints Veteran Point of Care Marketing Leader Sarah Bast as Chief Marketing Officer
Leading pharmaceutical marketing executive joins leadership team to accelerate innovation and strengthen partnerships across the life sciences industry WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology |
| 2026-06-30 |
OptimizeRx Launches CopayCue™, a Next-Generation Copay Activation Solution Powered by Real-Time Prescribing Intent
Enhanced technology delivers brand savings offers directly within the prescribing workflow, when HCP intent is highest WALTHAM, Mass., June 30, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences |
| 2026-06-25 |
OptimizeRx Launches Natural Language Audience Builder for Life Sciences DSPs and Agency Media Planning Platforms
Patent-pending, embeddable NLAB technology enables pharma and agency marketers to build custom, verified HCP audiences using natural-language prompts WALTHAM, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology |
| 2026-06-01 |
OptimizeRx to Participate in Upcoming Investor Conferences
WALTHAM, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced that management will participate in the |
| 2026-05-21 |
DeepIntent Becomes First Healthcare DSP to Integrate OptimizeRx’s Authenticated EHR Network
Powered by OptimizeRx’s new programmatic infrastructure, collaboration expands access to premium point of care inventory for life sciences marketers WALTHAM, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life |
| 2026-05-12 |
OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
– Q1 revenue totals $19.8 million – Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively – 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged at $21-$25 million – Paid off an incremental $2.7 million in principal from term loan |
| 2026-05-11 |
OptimizeRx Launches Programmatic Access to Authenticated EHR Advertising at Scale
Expands life sciences marketers’ reach at the validated point of care, enabling DSPs to directly integrate with OptimizeRx’s trusted EHR network for the first time WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare |
| 2026-04-29 |
OptimizeRx Releases 2026 Environmental, Social, and Governance (ESG) Report
WALTHAM, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, has published its Environmental, Social and |
| 2026-04-28 |
OptimizeRx Sets First Quarter 2026 Conference Call for May 12, 2026, at 4:30 p.m. ET
WALTHAM, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, will hold a conference call on Tuesday, May 12, 2026, at 4:30 |
| 2026-04-08 |
OptimizeRx Appoints Mary Varghese Presti to Board of Directors
Microsoft Health & Life Sciences COO brings expertise in scaling healthcare platforms, commercializing new technologies, and driving operational efficiency WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare solutions |
| 2026-03-05 |
UPDATE – OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
- Q4 revenue of $32.2 million - Q4 gross profit increased 9% year-over-year to $24.1 million - Q4 net income and adjusted EBITDA hit records at $5.0 million and $12.0 million, respectively - Updating 2026 revenue guidance to $109-$114 million and adjusted EBITDA guidance to $21-$25 million |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-08-12 | OPRX 2nd Quarter 2026 Earnings Conference Call | Earnings call |
| 2026-06-03 | William Blair & Company’s 46th Annual Growth Stock Conference | Conference |
| 2026-06-02 | Stifel 2026 Boston Cross Sector 1x1 Conference | Conference |
| 2026-05-12 | OPRX 1st Quarter 2026 Earnings Conference Call | Earnings call |
| 2026-03-05 | OPRX 4th Quarter 2025 Earnings Conference Call | Earnings call |
| 2025-11-06 | OPRX 3rd Quarter 2025 Earnings Conference Call | Earnings call |
| 2025-09-11 | 9th Annual Lake Street Capital Best Ideas Growth Conference | Conference |
| 2025-08-07 | OPRX 2nd Quarter 2025 Earnings Conference Call | Earnings call |
| 2025-06-05 | 45th Annual William Blair Growth Stock Conference | Conference |
| 2025-06-03 | Stifel 2025 Boston Cross Sector 1x1 Conference | Conference |
| 2025-05-22 | B. Riley Securities 25th Annual Investor Conference | Conference |